Member Directory

Cancer Research Horizons is the innovation engine of Cancer Research UK – the world’s largest charitable funder of cancer research. We bring together the best minds, bold ideas, and the right partners to bridge the gap between academic research and taking drugs to market. We focus on the tougher, more profound ideas that can lead to true innovation, translating them into effective treatments and diagnostics for cancer patients.

To date we’ve played an instrumental role in forming over 70 startup companies. We’ve helped bring 11 cancer drugs to market, borne out of Cancer Research UK’s pioneering research. Through these drugs, we have enabled in excess of 6 million courses of treatment for cancer patients worldwide.

With access to Cancer Research UK’s network of 4,000 exceptional researchers, and over £400m of annual research spend, we’re a powerful partner in the fight to conquer cancer. By uniting our commercial partnerships and therapeutic innovation capabilities, Cancer Research Horizons is uniquely placed to support translational funding, entrepreneurial development, licensing and collaboration, start-up creation, and offer a full spectrum of drug discovery and clinical capabilities.

Every penny we make goes back into funding the next bold steps, to help bring forward the day when all cancers and conquered.

Cancer Research Technology (CRT) is dedicated to advancing discoveries to beat cancer. We develop and commercialise exciting new discoveries in cancer research, working closely with leading clinical and academic institutions, pharmaceutical companies and biotechs worldwide. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. . . CRT is owned by Cancer Research UK, the world’s largest charitable funder of cancer research and we’re uniquely placed to capitalise on the research and connections of our parent organisation.

Carocell Bio are developing novel peptides to more safely and effectively treat inflammatory diseases.

Catalent, Inc. is a global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,500 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply approximately 70 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of nearly 18,000 includes more than 3,000 scientists and technicians.

Point of contact:
Peter F. Farmer, Senior Account Director


Discovery services in oncology, immunology and respiratory

CPI provides assets and resources to support innovations in the manufacture of biologics. Utilising our state of the art facilities and technical expertise, we help our clients to de-risk process development through proof of concept testing to accelerate the commercialisation of new processes and technologies. . . Our skilled team of scientists, engineers and sector specialists can help companies of all sizes to develop, demonstrate, prototype and scale-up innovations that could be beneficial to biologics manufacture and provision. From initial programme scoping and planning through to process demonstration and scale-up we have a range of services which can be tailored to meet your needs. . . Collaboration with CPI will enable the biologics industry to capitalise on its strong research and development pipeline and make more therapies available for unmet clinical needs. We support the commercialisation of research by promoting collaboration with industry across the supply chain from research through to manufacture and clinic.

Cerevance is a new pharmaceutical company focused on central nervous system diseases. Our strengths include a powerful technology platform, a pipeline of novel discovery-stage and clinical-stage compounds, and a proven team. We believe that we are well positioned to deliver life-changing therapeutics for patients who have brain-related disorders, while creating value for our employees and shareholders.

CFGI is an international, non-audit, accounting advisory firm free of auditor independence restrictions. Consisting of ex-Big4 professionals, CFGI is strategically positioned to help companies and private equity sponsors through a range of routine and complex business scenarios.

Founded in the US in 2000, and now operating across the UK, CFGI is ideally placed to support companies throughout their lifecycle, from ambitious high growth pre-revenue start-ups, right through to established, commercial public companies. CFGI has expertise across a wide range of sectors, with a particular specialism in Lifesciences and Healthcare.

Operating as a hands-on extension of your finance team, CFGI works alongside your people, serving in a variety of roles – from technical accounting advisor to M&A support, to IPO readiness to listed company financial reporting – and delivering seamless support services. Without the independence restrictions of an audit practice, CFGI’s model allows for a rapid, flexible and cost competitive response to deliver a tailored solution for each challenge encountered.

The range of areas of support include:
» Technical accounting
» IPO readiness and support
» Interim management
» Valuation
» Audit assistance
» Cybersecurity
» Risk advisory and controls
» Transaction services
» ESG implementation
» Financial reporting
» Business transformation
» Tax services

Contact Paul Cooper our UK Healthcare and Lifesciences lead at